207 related articles for article (PubMed ID: 8482557)
41. Treatment of advanced and recurrent ovarian carcinoma with cyclophosphamide, doxorubicin, and cisplatin.
Belinson JL; McClure M; Ashikaga T; Krakoff IH
Cancer; 1984 Nov; 54(9):1983-90. PubMed ID: 6548172
[TBL] [Abstract][Full Text] [Related]
42. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
Hainsworth JD; Burnett LS; Jones HW; Grosh WW; Johnson DH; Greco FA
J Clin Oncol; 1990 Mar; 8(3):502-8. PubMed ID: 2407811
[TBL] [Abstract][Full Text] [Related]
43. Randomised trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4'-epi-doxorubicin in the treatment of advanced ovarian cancer.
Hernádi Z; Juhász B; Póka R; Lampé LG
Int J Gynaecol Obstet; 1988 Oct; 27(2):199-204. PubMed ID: 2903085
[TBL] [Abstract][Full Text] [Related]
44. Chemotherapy for stage III-IV ovarian cancer: the CAP-regimen in previously untreated patients.
Meerpohl HG; Pfleiderer A; Kleine W; Teufel G
Onkologie; 1982 Oct; 5(5):238-41. PubMed ID: 6760025
[TBL] [Abstract][Full Text] [Related]
45. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
[TBL] [Abstract][Full Text] [Related]
46. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
Sutton GP; Stehman FB; Einhorn LH; Roth LM; Blessing JA; Ehrlich CE
J Clin Oncol; 1989 Feb; 7(2):223-9. PubMed ID: 2915238
[TBL] [Abstract][Full Text] [Related]
47. Treatment of advanced epithelial ovarian cancer with a cis-dichloro-diammine platinum, cyclophosphamide, and bleomycin combination.
Israël L; Breau JL; Morère JF; Aguilera J
Am J Clin Oncol; 1988 Feb; 11(1):7-11. PubMed ID: 2449068
[TBL] [Abstract][Full Text] [Related]
48. Intraperitoneal cisplatin chemotherapy versus abdominopelvic irradiation in ovarian carcinoma patients after second look laparotomy. A reassessment based on mature data.
Ben-Baruch G; Menczer J; Feldman B; Rizel S; Brenner H
Eur J Gynaecol Oncol; 1994; 15(4):272-6. PubMed ID: 7957334
[TBL] [Abstract][Full Text] [Related]
49. Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission.
Dufour P; Bergerat JP; Barats JC; Giron C; Duclos B; Dellenbach P; Ritter J; Renaud R; Audhuy B; Oberling F
Cancer; 1994 Apr; 73(7):1865-9. PubMed ID: 8137212
[TBL] [Abstract][Full Text] [Related]
50. Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer.
Rothenberg ML; Ozols RF; Glatstein E; Steinberg SM; Reed E; Young RC
J Clin Oncol; 1992 May; 10(5):727-34. PubMed ID: 1569445
[TBL] [Abstract][Full Text] [Related]
51. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia.
Lancet; 1987 Aug; 2(8555):353-9. PubMed ID: 2886821
[TBL] [Abstract][Full Text] [Related]
52. Cisplatin and cyclophosphamide in early epithelial ovarian carcinoma.
Chiara S; Conte PF; Bruzzone M; Falcone A; Sertoli MR; Carnino F; Mossetti C; Iura R; Durando C; Guercio E
Chemioterapia; 1987 Oct; 6(5):380-3. PubMed ID: 3427698
[TBL] [Abstract][Full Text] [Related]
53. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
[TBL] [Abstract][Full Text] [Related]
54. A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer.
Kohn EC; Sarosy GA; Davis P; Christian M; Link CE; Ognibene FP; Sindelar WF; Jacob J; Steinberg SM; Premkumar A; Reed E
Gynecol Oncol; 1996 Aug; 62(2):181-91. PubMed ID: 8751547
[TBL] [Abstract][Full Text] [Related]
55. Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.
Conte PF; Bruzzone M; Carnino F; Chiara S; Donadio M; Facchini V; Fioretti P; Foglia G; Gadducci A; Gallo L
J Clin Oncol; 1991 Apr; 9(4):658-63. PubMed ID: 2066762
[TBL] [Abstract][Full Text] [Related]
56. Accurate laboratory predictions of the clinical response of patients with advanced ovarian cancer to treatment with cyclophosphamide, doxorubicin, and cisplatin.
Stratton JA; Kucera PR; Rettenmaier MA; Dobashi K; Micha JP; Braly PS; Berman ML; DiSaia PJ
Gynecol Oncol; 1986 Nov; 25(3):302-10. PubMed ID: 3781341
[TBL] [Abstract][Full Text] [Related]
57. Tumor debulking followed by immediate combination chemotherapy in advanced ovarian carcinoma. Phase II.
Vardi JR; Tadros GH; Zamurovic D; Rafla SD
Acta Obstet Gynecol Scand; 1992 Jul; 71(5):361-7. PubMed ID: 1326212
[TBL] [Abstract][Full Text] [Related]
58. Risks and benefits of cisplatin in ovarian cancer. A quality-adjusted survival analysis.
Willemse PH; van Lith J; Mulder NH; Aalders JG; Bouma J; de Vries EG; Sleijfer DT
Eur J Cancer; 1990 Mar; 26(3):345-52. PubMed ID: 2141492
[TBL] [Abstract][Full Text] [Related]
59. Consolidation radiation therapy following cytoreductive surgery, chemotherapy and second-look laparotomy for epithelial ovarian carcinoma: long-term follow-up.
Goldberg H; Stein ME; Steiner M; Sprecher E; Beck D; Kuten A
Tumori; 2001; 87(4):248-51. PubMed ID: 11695352
[TBL] [Abstract][Full Text] [Related]
60. Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer.
Marth C; Tropé C; Vergote IB; Kristensen GB
Eur J Cancer; 1998 Jul; 34(8):1175-80. PubMed ID: 9849475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
